middle.news
Cyclopharm’s U.S. Surge Drives Record Revenue, Eyes 300 Installations by 2026
9:48am on Monday 2nd of February, 2026 AEDT
•
Healthcare
Read Story
Cyclopharm’s U.S. Surge Drives Record Revenue, Eyes 300 Installations by 2026
9:48am on Monday 2nd of February, 2026 AEDT
Key Points
Record $32.3 million revenue, up 17% year-on-year
U.S. Technegas revenue surges 226% after FDA approval
Third-party distribution revenue grows 26%, driven by consumables
Ultralute asset impaired by $2.7 million due to delayed commercialisation
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cyclopharm (ASX:CYC)
OPEN ARTICLE